(Q34093019)

31 July 2017

1 reference

title

Insulin glargine: a review of its therapeutic use as a long-acting agent for the management of type 1 and 2 diabetes mellitus (English)

1 reference

31 July 2017

0 references

1 reference

K McKeage

1

1 reference

PubMed ID

11577797

31 July 2017

K L Goa

series ordinal

2

1 reference

31 July 2017

1 January 2001

1 reference

31 July 2017

1 reference

31 July 2017

61

1 reference

31 July 2017

11

1 reference

31 July 2017

1599-1624

1 reference

https://scigraph.springernature.com/pub.10.2165/00003495-200161110-00007

31 July 2017

0 references

cites work

Basal insulin therapy in type 2 diabetes: 28-week comparison of insulin glargine (HOE 901) and NPH insulin

1 reference

12 December 2020

Time-action profile of the long-acting insulin analog insulin glargine (HOE901) in comparison with those of NPH insulin and placebo

1 reference

12 December 2020

Growth promoting and metabolic activity of the human insulin analogue [GlyA21,ArgB31,ArgB32]insulin (HOE 901) in muscle cells

1 reference

12 December 2020

Efficacy and safety of HOE 901 versus NPH insulin in patients with type 1 diabetes. The European Study Group of HOE 901 in type 1 diabetes

1 reference

12 December 2020

Physiological responses during hypoglycaemia induced by regular human insulin or a novel human analogue, insulin glargine

1 reference

12 December 2020

Insulin analogs with improved pharmacokinetic profiles

1 reference

12 December 2020

Nocturnal glucose control and free insulin levels in children with type 1 diabetes by use of the long-acting insulin HOE 901 as part of a three-injection regimen

1 reference

12 December 2020

Insulin glargine: the first clinically useful extended-acting insulin in half a century?

1 reference

12 December 2020

Less nocturnal hypoglycemia and better post-dinner glucose control with bedtime insulin glargine compared with bedtime NPH insulin during insulin combination therapy in type 2 diabetes. HOE 901/3002 Study Group.

1 reference

12 December 2020

Insulin analogues and their potential in the management of diabetes mellitus

1 reference

12 December 2020

Cotherapy with recombinant human insulin-like growth factor I and insulin improves glycemic control in type 1 diabetes. RhIGF-I in IDDM Study Group

1 reference

12 December 2020

Epidemiology of type II diabetes: an international perspective

1 reference

12 December 2020

Treatment satisfaction and psychological well-being with insulin glargine compared with NPH in patients with Type 1 diabetes

1 reference

12 December 2020

Pharmacokinetics of 125I-labeled insulin glargine (HOE 901) in healthy men: comparison with NPH insulin and the influence of different subcutaneous injection sites.

1 reference

12 December 2020

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group

1 reference

12 December 2020

A 16-week comparison of the novel insulin analog insulin glargine (HOE 901) and NPH human insulin used with insulin lispro in patients with type 1 diabetes.

1 reference

12 December 2020

The long acting human insulin analog HOE 901: characteristics of insulin signalling in comparison to Asp(B10) and regular insulin

1 reference

12 December 2020

Treatment with human analog (GlyA21, ArgB31, ArgB32) insulin glargine (HOE901) resolves a generalized allergy to human insulin in type 1 diabetes.

1 reference

12 December 2020

Comparison of insulin regimens in patients with non-insulin-dependent diabetes mellitus

1 reference

12 December 2020

1998 clinical practice guidelines for the management of diabetes in Canada. Canadian Diabetes Association.

1 reference

12 December 2020

Pharmacokinetics and pharmacodynamics of subcutaneous injection of long-acting human insulin analog glargine, NPH insulin, and ultralente human insulin and continuous subcutaneous infusion of insulin lispro.

1 reference

12 December 2020

1 reference

12 December 2020

Less hypoglycemia with insulin glargine in intensive insulin therapy for type 1 diabetes. U.S. Study Group of Insulin Glargine in Type 1 Diabetes.

1 reference

12 December 2020

1 reference

12 December 2020

Insulin analogues: impact of cell model characteristics on results and conclusions regarding mitogenic properties

1 reference

12 December 2020

The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group

1 reference

12 December 2020

Effect of intensive diabetes treatment on the development and progression of long-term complications in adolescents with insulin-dependent diabetes mellitus: Diabetes Control and Complications Trial. Diabetes Control and Complications Trial Research

1 reference

12 December 2020

Effects of the long-acting insulin analog insulin glargine on cultured human skeletal muscle cells: comparisons to insulin and IGF-I.

1 reference

12 December 2020

1 reference

12 December 2020

Correlations of receptor binding and metabolic and mitogenic potencies of insulin analogs designed for clinical use

1 reference

12 December 2020

Emerging epidemic of type 2 diabetes in youth

1 reference

12 December 2020

Safety of insulin glargine

1 reference

12 December 2020

Long acting insulin analogues: can they provide a basal insulin level?

1 reference

12 December 2020

Basal insulin glargine (HOE 901) versus NPH insulin in patients with type 1 diabetes on multiple daily insulin regimens. U.S. Insulin Glargine (HOE 901) Type 1 Diabetes Investigator Group.

1 reference

12 December 2020

10.2165/00003495-200161110-00007

Identifiers

DOI

1 reference

PubMed ID

11577797

Dimensions Publication ID

31 July 2017

0 references

1 reference

PubMed ID

11577797